Condition: Autologous Stem Cell Transplant · Classic Hodgkin Lymphoma · Sponsor: Masonic Cancer Center, University of Minnesota
This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant.
This description comes directly from the study's public registry record.
Sanjal Desai · 612-625-5469 · desai171@umn.edu
Roberta Nicklow · nickl004@umn.edu
Always discuss trial participation with your own doctor first.
| Masonic Cancer Center | Minneapolis, Minnesota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06377540